HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gabor Halmos Selected Research

AN 238

7/2006Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
6/2006Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
9/2005Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
7/2005Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
5/2005Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
2/2005Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
2/2004Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
10/2003Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
5/2003Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
2/2002Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gabor Halmos Research Topics

Disease

64Neoplasms (Cancer)
04/2022 - 01/2002
16Prostatic Neoplasms (Prostate Cancer)
01/2017 - 02/2002
15Carcinoma (Carcinomatosis)
08/2010 - 02/2002
7Breast Neoplasms (Breast Cancer)
08/2009 - 09/2003
6Endometrial Neoplasms (Endometrial Cancer)
04/2022 - 08/2003
6Lymphoma (Lymphomas)
01/2017 - 10/2004
4Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 03/2005
4Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 02/2002
4Glioblastoma (Glioblastoma Multiforme)
01/2022 - 02/2005
4Neoplasm Metastasis (Metastasis)
01/2020 - 01/2005
4Uveal melanoma
01/2020 - 10/2013
4Pancreatic Neoplasms (Pancreatic Cancer)
05/2013 - 10/2005
4Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
02/2013 - 03/2011
3Renal Cell Carcinoma (Grawitz Tumor)
01/2017 - 08/2005
3Adenocarcinoma
01/2017 - 10/2002
3Melanoma (Melanoma, Malignant)
10/2013 - 07/2005
3Liver Neoplasms (Liver Cancer)
10/2012 - 02/2005
3Lung Neoplasms (Lung Cancer)
10/2011 - 11/2005
3Colonic Neoplasms (Colon Cancer)
10/2009 - 02/2002
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2006 - 05/2003
2Hepatocellular Carcinoma (Hepatoma)
04/2008 - 02/2005
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2007 - 08/2005
2Glioma (Gliomas)
07/2005 - 02/2005
2Body Weight (Weight, Body)
05/2005 - 04/2005
1Hodgkin Disease (Hodgkin's Disease)
12/2020
1Chromosome Aberrations (Chromosome Abnormalities)
04/2017
1Myocardial Infarction
02/2014
1Gynatresia
01/2014
1Hypoxia (Hypoxemia)
01/2014
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2012
1Lower Urinary Tract Symptoms
04/2011
1Leukemia
08/2010

Drug/Important Bio-Agent (IBA)

28Messenger RNA (mRNA)IBA
04/2022 - 02/2002
23Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA
04/2022 - 01/2002
20Gonadotropin-Releasing Hormone (GnRH)FDA Link
01/2020 - 09/2003
16Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
12/2020 - 02/2002
16BombesinIBA
10/2012 - 10/2003
16AN 204 (AN 201)IBA
06/2007 - 02/2002
15Proteins (Proteins, Gene)FDA Link
01/2018 - 04/2005
13LigandsIBA
04/2022 - 10/2002
12Doxorubicin (Adriamycin)FDA LinkGeneric
05/2013 - 04/2003
11LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
01/2020 - 09/2003
11AndrogensIBA
04/2012 - 02/2002
11AN 238IBA
07/2006 - 02/2002
10Somatostatin Receptors (Somatostatin Receptor)IBA
06/2018 - 02/2002
10Gastrin-Releasing PeptideIBA
02/2013 - 01/2005
9AN 215IBA
07/2006 - 10/2003
8somatotropin releasing hormone receptorIBA
01/2017 - 06/2002
8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2012 - 02/2005
7lysine(6)-doxorubicin LHRHIBA
01/2020 - 09/2003
7RC 121IBA
08/2010 - 02/2002
7AN 207IBA
06/2007 - 04/2005
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2013 - 08/2005
5MZ-J-7-138IBA
04/2012 - 07/2005
5Insulin-Like Growth Factor I (IGF-1)IBA
03/2006 - 04/2002
4Hca(6)-Leu(13)-psi(CH2N)-Tac(14)- bombesin(6-14)IBA
10/2012 - 01/2005
4cetrorelix (Cetrotide)FDA Link
04/2012 - 09/2007
4Peptides (Polypeptides)IBA
03/2011 - 07/2006
4Insulin-Like Growth Factor II (Somatomedin A)IBA
12/2008 - 11/2003
4MZ-J-7-118IBA
09/2007 - 01/2005
4Protein Isoforms (Isoforms)IBA
08/2006 - 06/2002
3Har(29)- Arg(28) Nle(27) Orn(21) His(20) Orn(12,) Abu(15) His(11) Tyr(Me)(10) Har(9) Ala(8) Fpa(5,6) Arg(2) (PhAc-Ada)(0)-Tyr(1) GHRH(1-29)NH2IBA
01/2022 - 02/2012
3Hormones (Hormone)IBA
01/2018 - 10/2004
3Epidermal Growth Factor (EGF)IBA
09/2007 - 08/2005
3RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
06/2007 - 10/2003
3ErbB Receptors (EGF Receptor)IBA
02/2007 - 10/2003
3JV 1-38IBA
08/2006 - 11/2003
2Antineoplastic Agents (Antineoplastics)IBA
01/2022 - 10/2005
2Human Growth Hormone (Saizen)FDA LinkGeneric
01/2017 - 10/2004
2Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA
10/2011 - 04/2002
2PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2IBA
10/2009 - 02/2007
2Estrogens (Estrogen)FDA Link
08/2009 - 09/2003
2Docetaxel (Taxotere)FDA Link
02/2007 - 09/2006
2Member 1 Subfamily B ATP Binding Cassette TransporterIBA
07/2006 - 11/2005
2Membrane Transport Proteins (Biological Pump)IBA
11/2005 - 09/2005
2Triptorelin Pamoate (Trelstar)FDA Link
08/2005 - 10/2003
2Insulin-Like PeptidesIBA
02/2004 - 11/2003
2vapreotideIBA
05/2003 - 04/2002
2pentetreotide (OctreoScan)FDA Link
05/2003 - 04/2003
2Membrane Proteins (Integral Membrane Proteins)IBA
10/2002 - 06/2002
1NeuropeptidesIBA
12/2020
1Hypothalamic HormonesIBA
01/2018
1MR 356IBA
02/2014
1N-Me-Tyr1,D-Ala2,Asn8,Arg29-NHCH3-JI-38IBA
02/2014
1JI-38IBA
02/2014
1Gonadal Steroid Hormones (Sex Hormones)IBA
05/2013
1matrigelIBA
02/2012
1EnzymesIBA
02/2012
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
02/2012
1ImmunosorbentsIBA
02/2012
1Type I Vasoactive Intestinal Polypeptide ReceptorsIBA
10/2011
1Type II Vasoactive Intestinal Peptide ReceptorsIBA
10/2011
1CytokinesIBA
05/2011
1glutaric acidIBA
08/2009

Therapy/Procedure

32Therapeutics
01/2022 - 01/2002
20Drug Therapy (Chemotherapy)
08/2009 - 02/2002
3Aftercare (After-Treatment)
07/2006 - 02/2005
3Injections
09/2003 - 02/2002
2Investigational Therapies (Experimental Therapy)
06/2007 - 08/2005
1Uterine Myomectomy
01/2014